SAVE BC, Canada

Registration Status: Completed

Objective: Premature atherosclerotic cardiovascular disease (ASCVD) is highly heritable. As a consequence, the first degree relatives (FDRs) of such patients are at increased risk for cardiovascular events. Professional society guidelines recommend that the FDRs of patients with premature ASCVD be screened. However, in practice screening rates are very low, and no programs exist in British Columbia (BC) for identifying and screening families with very premature ASCVD. The Study to Avoid cardioVascular Events in British Columbia (SAVE BC) has been designed as a provincial program aimed at identifying and following index cases with premature ASCVD and their FDRs. Index cases are eligible if they are men ≤50 and women≤55 years who present with stable angina or acute coronary syndrome and have angiographic evidence of coronary disease with at least one lesion with ≥50% stenosis. All participants will undergo a structured cardiovascular risk assessment. FDRs will be screened for sub-clinical atherosclerosis via coronary calcium score or CT coronary angiogram. All participants will be followed longitudinally, and biological samples will be obtained for research studies.

Registered Biobank Name SAVE BC
Biobank Leader Genevieve Rocheleau
Country Canada
Email for biobank inquiries grocheleau@providencehealth.bc.ca
Principal Investigator Simon Primstone, Liam Brunham
Website
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Biospecimen Collected:
Cohort Highlights